Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07431177 · ClinicalTrials.gov registry record · Phase 2
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
A Phase 2 study of Non-segmental Vitiligo, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
- 6
- Study locations
NCT07431177: Recruiting Phase 2 study of Non-segmental Vitiligo, sponsored by Novartis Pharmaceuticals.
NCT07431177 is a Phase 2 study of Non-segmental Vitiligo that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 210 participants, below the 247-participant average among 9 other Non-segmental Vitiligo trials with a reported enrollment target (15% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07431177, a Phase 2 study of Non-segmental Vitiligo, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
- 6
- Study locations
Study Summary
The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.
Primary Outcome
The F-VASI assesses the percentage of facial area affected by vitiligo. It ranges from 0 to 3.5, with 0 representing no vitiligo on the face and 3.5 representing complete depigmentation of the assessed facial areas.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GIA632
Study Locations (6)
New South Wales
- Novartis Investigative Site - Sydney
- Novartis Investigative Site - Waitara
Alabama
- Cahaba Derm and skin hlth ctr 27 - Birmingham
Florida
- Miami Derm and Laser Institute - Miami
Michigan
- Revival Research Institute - Troy
Ontario
- Novartis Investigative Site - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2030-02-14 |
| Phase | Phase 2 |
What NCT07431177 shows while recruiting
NCT07431177 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, below the 247-participant average among 9 other Non-segmental Vitiligo trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Non-segmental Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07431177 lists 6 locations in 5 states (New South Wales, Alabama, Florida).
Frequently Asked Questions
What is clinical trial NCT07431177 about?
NCT07431177 is a clinical study titled "A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo". The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.
What is the current status of trial NCT07431177?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2026-03-09. Estimated completion is 2030-02-14.
What conditions does trial NCT07431177 study?
This clinical trial studies the following conditions: Non-segmental Vitiligo.
What interventions are being tested in trial NCT07431177?
The interventions under investigation include: Placebo (DRUG), GIA632 (DRUG).
Who is sponsoring clinical trial NCT07431177?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07431177 being conducted?
This trial has 6 study locations across Alabama, Florida, Michigan, New South Wales, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-segmental Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07431177's enrollment target sits among peer trials
210 5th of 9 higher than 5 of 9 other Non-segmental Vitiligo trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-segmental Vitiligo trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
RECRUITING · Phase 2
-
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
RECRUITING · Phase 2
-
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI